DaVita Healthcare Partners (NYSE: DVA ) will report Q3 results on November 6 after the close. The conference call will begin at 3:00 MT/5:00 pm ET. Consensus view is EPS of $0.90 on revenues of $3.2B. Post your comment!
Q3 income from continuing operations (excluding DVA ) of $1.6B of $0.77 per share vs. $1B and $0.50 one year ago. This year's Q boosted by net discrete tax benefit of
Morgan Stanley (NYSE: MS ): Q3 EPS (Excl. DVA ) of $0.77 beats by $0.23 . Revenue (Excl. DVA ) of $8.7B (+7.4% Y/Y) beats by $530M . Press Release Post your comment!
20 per share. Net interest income of $10.4B flat from a year ago. Noninterest income gained 2% Y/Y, when excluding DVA adjustments. Net charge-offs of $1B fell 38%. Net charge-off ratio of 0.46 compares to 0.73 one year ago. Noninterest
tax benefit, and gains from PE, MSR and DVA , EPS was actually in-line. JPM 3Q14 ..... 0.09 - Gains on: PE 0.05 MSR 0.01 DVA 0.06 Adj. EPS 1.38 Source: Westend511 ..... revenue of $3.5b (+2% y/y, excluding DVA ) also beat consensus estimate thanks to
offset by higher expenses and taxes, and a smaller reserve release, according to Fitch Ratings. Excluding the impact of CVA/ DVA , Citi's adjusted return on assets (ROA) of 77 basis points (bps) and reported ROA of 72bps still lag pee
Net income (excl. DVA ) of $3.7B or $1.15 per share is up 13% from a year ago. Citicorp ..... revenue of $18B up 8% Y/Y; net income of $3.2B down 4%. Excluding DVA , net income rose 1%. Operating expenses of $11.5B up 11% thanks
Citigroup (NYSE: C ): Q3 EPS (Excl. CVA/ DVA ) of $1.15 beats by $0.03 . Revenue (Excl. CVA/ DVA ) of $19.97B (+9.5% Y/Y) beats by $920M . Press Release Post your comment!
4B gains a strong 4% from a year ago. Corporate & Investment Bank net income of $1.485B down 34% Y/Y; excluding the DVA , net income fell 40%. Banking revenue of $2.7B fell 6% - investment banking fees grew 2% thanks to strong equity underwriting
Speaking of diabetes, how do you view DaVita HealthCare Partners DVA as a potential Berkshire Hathaway ..... certain amount of attractiveness for DaVita in that diabetes is a big contributor to dialysis and DaVita is one of the largest dialysis providers